James Huang

James is an industry veteran with over 30 years of biotech experience. He is a successful entrepreneur and investor dedicated to investing in disruptive innovation and supporting entrepreneurs to build global companies that will transform the lives of patients around the world. He founded Panacea Venture to focus on investments in global innovative early and growth stage healthcare and life sciences companies.

James was previously Managing Partner of Kleiner Perkins (KPCB) China and Managing Partner at Vivo Ventures. Before joining Vivo in 2007, James was president of Anesiva, a biopharmaceutical company focused on pain-management treatments. He also held senior roles in business development, sales, marketing and R&D with Tularik Inc. (acquired by Amgen), GlaxoSmithKline LLC, Bristol-Meyers Squibb and ALZA Corp. (acquired by Johnson & Johnson).

James is currently a director at Kindstar Globalgene Technology Inc. (9960.HK), Connect Biopharma Holdings Limited (Nasdaq: CNTB) and several private companies.

James received an M.B.A. from the Stanford Graduate School of Business and a B.S. degree in chemical engineering from the University of California, Berkeley.